NASDAQ:NVCT Nuvectis Pharma (NVCT) Stock Price, News & Analysis $6.94 +0.32 (+4.83%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.53▼$6.9550-Day Range$5.98▼$7.2052-Week Range$5.85▼$15.50Volume20,102 shsAverage Volume96,913 shsMarket Capitalization$127.42 millionP/E RatioN/ADividend YieldN/APrice Target$21.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Nuvectis Pharma alerts: Email Address Nuvectis Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside202.6% Upside$21.00 Price TargetShort InterestHealthy12.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 2 Articles This WeekInsider TradingAcquiring Shares$29,021 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.29) to ($1.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.50 out of 5 starsMedical Sector296th out of 936 stocksPharmaceutical Preparations Industry135th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingNuvectis Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuvectis Pharma has only been the subject of 1 research reports in the past 90 days.Read more about Nuvectis Pharma's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted12.01% of the float of Nuvectis Pharma has been sold short.Short Interest Ratio / Days to CoverNuvectis Pharma has a short interest ratio ("days to cover") of 9.2.Change versus previous monthShort interest in Nuvectis Pharma has recently decreased by 18.13%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuvectis Pharma does not currently pay a dividend.Dividend GrowthNuvectis Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVCT. Previous Next 3.9 News and Social Media Coverage News SentimentNuvectis Pharma has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Nuvectis Pharma this week, compared to 1 article on an average week.Search Interest2 people have searched for NVCT on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Nuvectis Pharma to their MarketBeat watchlist in the last 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvectis Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $29,021.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders38.85% of the stock of Nuvectis Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.77% of the stock of Nuvectis Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nuvectis Pharma's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nuvectis Pharma are expected to decrease in the coming year, from ($1.29) to ($1.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvectis Pharma is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvectis Pharma is -4.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvectis Pharma has a P/B Ratio of 9.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Nuvectis Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED will cut rates any day now. But there's one indicator that's flashing a BIG warning sign to investors.Take these 4 steps to protect your retirement here. About Nuvectis Pharma Stock (NASDAQ:NVCT)Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Read More NVCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCT Stock News HeadlinesJuly 19, 2024 | theglobeandmail.comNuvectis Pharma Stands Out as a Unique Innovator in the Fast-Growing Precision Medicine MarketMay 28, 2024 | investorplace.com7 Penny Biotech Stocks to Triple Your InvestmentJuly 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.May 20, 2024 | entrepreneur.comThe Veteran Pharma Founders That Keep Buying Their Own NASDAQ StockMay 16, 2024 | seekingalpha.comNuvectis Pharma: An Interesting Early Pipeline Does Not Justify A BuyMay 16, 2024 | globenewswire.comNuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor ConferenceMay 8, 2024 | markets.businessinsider.comStrong Buy Rating for Nuvectis Pharma on Robust Financials and Promising Oncology Drug TrialsMay 8, 2024 | finance.yahoo.comNuvectis Pharma Inc Reports Q1 2024 Financial OutcomesJuly 26, 2024 | InvestorPlace (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.May 7, 2024 | investorplace.comNVCT Stock Earnings: Nuvectis Pharma Beats EPS for Q1 2024April 17, 2024 | finance.yahoo.comIs Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?April 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT) and Invivyd (IVVD)April 8, 2024 | finanznachrichten.deNuvectis Pharma, Inc.: Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 8, 2024 | markets.businessinsider.comNuvectis Pharma: Data Confirms Robust Activity Of NXP900 - Quick FactsApril 8, 2024 | finance.yahoo.comNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 8, 2024 | globenewswire.comNuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell LinesApril 2, 2024 | investorplace.com5 Healthcare Stocks to Buy for 2024March 21, 2024 | finance.yahoo.comInsider Buys Additional US$51k In Nuvectis Pharma StockSee More Headlines Receive NVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NVCT CUSIPN/A CIK1875558 Webwww.nuvectis.com Phone201-614-3150FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$21.00 Low Stock Price Target$21.00 Potential Upside/Downside+202.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,260,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-141.57% Return on Assets-103.98% Debt Debt-to-Equity RatioN/A Current Ratio3.46 Quick Ratio3.46 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book9.91Miscellaneous Outstanding Shares18,360,000Free Float11,225,000Market Cap$127.42 million OptionableNot Optionable Beta0.46 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Ron Bentsur M.B.A. (Age 58)Co-Founder, Chairman, CEO & President Comp: $1.12MDr. Enrique Poradosu Ph.D. (Age 57)Co-Founder, Executive VP, Chief Scientific & Business Officer Comp: $705.5kMr. Shay Shemesh (Age 40)Co-Founder, Executive VP, Chief Development & Operations Officer Comp: $705.5kMr. Michael Carson CPA (Age 48)Vice President of Finance Key CompetitorsTheravance BiopharmaNASDAQ:TBPHHeron TherapeuticsNASDAQ:HRTXOculisNASDAQ:OCSAltimmuneNASDAQ:ALTRevance TherapeuticsNASDAQ:RVNCView All CompetitorsInsiders & InstitutionsBaxter Bros Inc.Bought 12,500 shares on 7/16/2024Ownership: 0.068%Baldwin Brothers LLC MABought 14,500 shares on 7/12/2024Ownership: 0.918%Ron BentsurBought 1,940 shares on 5/14/2024Total: $13,075.60 ($6.74/share)Ron BentsurBought 2,000 shares on 5/10/2024Total: $12,800.00 ($6.40/share)Enrique PoradosuBought 500 shares on 5/10/2024Total: $3,145.00 ($6.29/share)View All Insider TransactionsView All Institutional Transactions NVCT Stock Analysis - Frequently Asked Questions How have NVCT shares performed this year? Nuvectis Pharma's stock was trading at $8.34 on January 1st, 2024. Since then, NVCT shares have decreased by 16.8% and is now trading at $6.94. View the best growth stocks for 2024 here. How were Nuvectis Pharma's earnings last quarter? Nuvectis Pharma, Inc. (NASDAQ:NVCT) posted its earnings results on Tuesday, May, 7th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.15. When did Nuvectis Pharma IPO? Nuvectis Pharma (NVCT) raised $19 million in an initial public offering on Friday, February 4th 2022. The company issued 3,200,000 shares at $5.00-$7.00 per share. Who are Nuvectis Pharma's major shareholders? Nuvectis Pharma's top institutional shareholders include Baldwin Brothers LLC MA (0.92%) and Baxter Bros Inc. (0.07%). Insiders that own company stock include Marlio Charles Mosseri, Enrique Poradosu, Shay Shemesh and Kenneth Hoberman. View institutional ownership trends. How do I buy shares of Nuvectis Pharma? Shares of NVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NVCT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.